Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11431122 | 0.85 | DAO (0.60) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL444120 | 0.83 | DAO (0.58) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL792991 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL11691177 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL14701887 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL7596452 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL7428616 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL7702540 | 0.80 | DAO (0.55) | DAOPOLBMEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL3925843 | 0.80 | DAO (0.55) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL7596457 | 0.78 | DAO (0.56) | DAOLMNAPOLBMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
| US-6117882-A | 5-HT4 agonists and antagonists | ELI LILLY AND COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| US-6069152-A | NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0526434-B1 | Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists | BOEHRINGER INGELHEIM ITALIA (IT) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999017772-A1 | 5HT4 AGONISTS AND ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0908459-A1 | 5-HT4 Agonists and antagonists | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0309423-A2 | New benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1989-03-29 | — | — | EP | disclosed |
| US-4061861-A | ANTIBIOTIC | ELI LILLY AND COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-4016282-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
| US-3980792-A | EFFECTIVE AGAINST GRAM-NEGATIVE AND GRAM-POSITIVE INFECTIONS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-14 | — | — | US | disclosed |
| US-3978223-A | UREIDOACETAMIDO-PENICILLINS FOR TREATING BACTERIAL INFECTIONS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-31 | — | — | US | disclosed |
| US-3974140-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
| US-3959258-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-25 | — | — | US | disclosed |
| US-3939149-A | BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | disclosed |
| US-3936442-A | ANTIBIOTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-03 | — | — | US | disclosed |
| US-3933795-A | Ureidoacetamido-penicillins | Konig, Hans-Bodo (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | DAO 1687/4885LMNA 4760/4885HTT 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.